【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 17
2 Introduction 18
2.1 Alzheimer Diagnostic Tests Overview 18
3 Products under Development 19
3.1 Alzheimer – Pipeline Products by Stage of Development 19
3.2 Alzheimer – Pipeline Products by Territory 20
3.3 Alzheimer – Pipeline Products by Regulatory Path 21
3.4 Alzheimer – Pipeline Products by Estimated Approval Date 22
3.5 Alzheimer – Ongoing Clinical Trials 23
4 Alzheimer – Pipeline Products under Development by Companies 24
4.1 Alzheimer Companies – Pipeline Products by Stage of Development 24
4.2 Alzheimer – Pipeline Products by Stage of Development 29
5 Alzheimer Companies and Product Overview 34
5.1 AC Immune SA Company Overview 34
5.1.1 AC Immune SA Pipeline Products & Ongoing Clinical Trials Overview 34
5.2 Acobiom Company Overview 37
5.2.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 37
5.3 Acumen Pharmaceuticals, Inc. Company Overview 40
5.3.1 Acumen Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.4 Adlyfe Inc. Company Overview 42
5.4.1 Adlyfe Inc. Pipeline Products & Ongoing Clinical Trials Overview 42
5.5 Advanced Genomic Technology, LLC Company Overview 43
5.5.1 Advanced Genomic Technology, LLC Pipeline Products & Ongoing Clinical Trials Overview 43
5.6 ADx NeuroSciences NV Company Overview 44
5.6.1 ADx NeuroSciences NV Pipeline Products & Ongoing Clinical Trials Overview 44
5.7 Akrivis Technologies, LLC Company Overview 58
5.7.1 Akrivis Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
5.8 Alere Inc. Company Overview 59
5.8.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview 59
5.9 Alzhyme Pty Ltd Company Overview 61
5.9.1 Alzhyme Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 61
5.10 Amarantus Bioscience Holdings, Inc. Company Overview 62
5.10.1 Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
5.11 Applied Proteomics, Inc. Company Overview 66
5.11.1 Applied Proteomics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.12 Araclon Biotech, S.L. Company Overview 67
5.12.1 Araclon Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 67
5.13 Banyan Biomarkers, Inc. Company Overview 68
5.13.1 Banyan Biomarkers, Inc. Pipeline Products & Ongoing Clinical Trials Overview 68
5.14 BioArctic Neuroscience AB Company Overview 69
5.14.1 BioArctic Neuroscience AB Pipeline Products & Ongoing Clinical Trials Overview 69
5.15 biOasis Technologies Inc. Company Overview 70
5.15.1 biOasis Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 70
5.16 Biomedical Development Corporation Company Overview 71
5.16.1 Biomedical Development Corporation Pipeline Products & Ongoing Clinical Trials Overview 71
5.17 BioSystems International Company Overview 72
5.17.1 BioSystems International Pipeline Products & Ongoing Clinical Trials Overview 72
5.18 C2N Diagnostics LLC Company Overview 73
5.18.1 C2N Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 73
5.19 Chronix Biomedical, Inc. Company Overview 74
5.19.1 Chronix Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 74
5.20 Cognoptix, Inc. Company Overview 76
5.20.1 Cognoptix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 76
5.21 Columbia University Company Overview 80
5.21.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 80
5.22 CompanDX Ltd. Company Overview 83
5.22.1 CompanDX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 83
5.23 Consejo Superior de Investigaciones Cientificas Company Overview 84
5.23.1 Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview 84
5.24 Cymedx Company Overview 86
5.24.1 Cymedx Pipeline Products & Ongoing Clinical Trials Overview 86
5.25 DiaGenic ASA Company Overview 87
5.25.1 DiaGenic ASA Pipeline Products & Ongoing Clinical Trials Overview 87
5.26 DiamiR LLC Company Overview 94
5.26.1 DiamiR LLC Pipeline Products & Ongoing Clinical Trials Overview 94
5.27 DiaPat GmbH Company Overview 95
5.27.1 DiaPat GmbH Pipeline Products & Ongoing Clinical Trials Overview 95
5.28 Diaxonhit S.A. Company Overview 96
5.28.1 Diaxonhit S.A. Pipeline Products & Ongoing Clinical Trials Overview 96
5.29 Dr. Grossegger & Drbal GmbH Company Overview 97
5.29.1 Dr. Grossegger & Drbal GmbH Pipeline Products & Ongoing Clinical Trials Overview 97
5.30 DS Pharma Biomedical Co., Ltd. Company Overview 98
5.30.1 DS Pharma Biomedical Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 98
5.31 Durin Technologies, Inc. Company Overview 99
5.31.1 Durin Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 99
5.32 Emory University Company Overview 100
5.32.1 Emory University Pipeline Products & Ongoing Clinical Trials Overview 100
5.33 Fianostics GmbH Company Overview 101
5.33.1 Fianostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 101
5.34 Gene Solutions LLC Company Overview 102
5.34.1 Gene Solutions LLC Pipeline Products & Ongoing Clinical Trials Overview 102
5.35 GeneNews Limited Company Overview 103
5.35.1 GeneNews Limited Pipeline Products & Ongoing Clinical Trials Overview 103
5.36 Genentech, Inc. Company Overview 105
5.36.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 105
5.37 Georg-August-Universitat Gottingen Company Overview 107
5.37.1 Georg-August-Universitat Gottingen Pipeline Products & Ongoing Clinical Trials Overview 107
5.38 Ghent University Company Overview 110
5.38.1 Ghent University Pipeline Products & Ongoing Clinical Trials Overview 110
5.39 HealthTell, Inc. Company Overview 111
5.39.1 HealthTell, Inc. Pipeline Products & Ongoing Clinical Trials Overview 111
5.40 ICDD-sas Company Overview 112
5.40.1 ICDD-sas Pipeline Products & Ongoing Clinical Trials Overview 112
5.41 Innovative California Biosciences International, Inc. Company Overview 115
5.41.1 Innovative California Biosciences International, Inc. Pipeline Products & Ongoing Clinical Trials Overview 115
5.42 Innovative Health Diagnostics Company Overview 122
5.42.1 Innovative Health Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 122
5.43 Institut National de la Sante et de la Recherche Medicale Company Overview 123
5.43.1 Institut National de la Sante et de la Recherche Medicale Pipeline Products & Ongoing Clinical Trials Overview 123
5.44 Instituto de Estructura de la Materia Company Overview 124
5.44.1 Instituto de Estructura de la Materia Pipeline Products & Ongoing Clinical Trials Overview 124
5.45 Integrated Diagnostics Inc. Company Overview 125
5.45.1 Integrated Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 125
5.46 Janssen Pharmaceutica N.V. Company Overview 126
5.46.1 Janssen Pharmaceutica N.V. Pipeline Products & Ongoing Clinical Trials Overview 126
5.47 KineMed, Inc. Company Overview 127
5.47.1 KineMed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 127
5.48 Laboratory Corporation of America Holdings Company Overview 128
5.48.1 Laboratory Corporation of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 128
5.49 McGill University Health Center Company Overview 130
5.49.1 McGill University Health Center Pipeline Products & Ongoing Clinical Trials Overview 130
5.50 Memory Dx, LLC Company Overview 131
5.50.1 Memory Dx, LLC Pipeline Products & Ongoing Clinical Trials Overview 131
5.51 Meso Scale Diagnostics LLC Company Overview 132
5.51.1 Meso Scale Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 132
5.52 Myriad Genetics, Inc. Company Overview 133
5.52.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 133
5.53 NanoSomiX, Inc. Company Overview 135
5.53.1 NanoSomiX, Inc. Pipeline Products & Ongoing Clinical Trials Overview 135
5.54 Nanosphere, Inc. Company Overview 137
5.54.1 Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview 137
5.55 Neuron Biopharma SA Company Overview 139
5.55.1 Neuron Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 139
5.56 NeuroQuest, Ltd. Company Overview 141
5.56.1 NeuroQuest, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 141
5.57 Neurotrope Bioscience, Inc. Company Overview 142
5.57.1 Neurotrope Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 142
5.58 NeuroVision Imaging LLC. Company Overview 143
5.58.1 NeuroVision Imaging LLC. Pipeline Products & Ongoing Clinical Trials Overview 143
5.59 Newcastle University Company Overview 144
5.59.1 Newcastle University Pipeline Products & Ongoing Clinical Trials Overview 144
5.60 NextGen Sciences Dx Inc Company Overview 146
5.60.1 NextGen Sciences Dx Inc Pipeline Products & Ongoing Clinical Trials Overview 146
5.61 Novel Bio-spectrum Technologies, Inc. Company Overview 147
5.61.1 Novel Bio-spectrum Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 147
5.62 Oligomerix, inc. Company Overview 148
5.62.1 Oligomerix, inc. Pipeline Products & Ongoing Clinical Trials Overview 148
5.63 OPKO Health, Inc. Company Overview 149
5.63.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 149
5.64 Orasi Medical, Inc. Company Overview 152
5.64.1 Orasi Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 152
5.65 Oregon Health & Science University Company Overview 156
5.65.1 Oregon Health & Science University Pipeline Products & Ongoing Clinical Trials Overview 156
5.66 Oryzon Genomics S.A. Company Overview 157
5.66.1 Oryzon Genomics S.A. Pipeline Products & Ongoing Clinical Trials Overview 157
5.67 Oxford Biodynamics Limited Company Overview 159
5.67.1 Oxford Biodynamics Limited Pipeline Products & Ongoing Clinical Trials Overview 159
5.68 PDx BioTech Company Overview 161
5.68.1 PDx BioTech Pipeline Products & Ongoing Clinical Trials Overview 161
5.69 PeriRx LLC Company Overview 162
5.69.1 PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview 162
5.70 Pre Diagnostics AS Company Overview 163
5.70.1 Pre Diagnostics AS Pipeline Products & Ongoing Clinical Trials Overview 163
5.71 Predemtec GmbH Company Overview 164
5.71.1 Predemtec GmbH Pipeline Products & Ongoing Clinical Trials Overview 164
5.72 ProMIS Neurosciences Inc. Company Overview 165
5.72.1 ProMIS Neurosciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 165
5.73 Proplex Technologies, Llc Company Overview 167
5.73.1 Proplex Technologies, Llc Pipeline Products & Ongoing Clinical Trials Overview 167
5.74 Protagen AG Company Overview 169
5.74.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 169
5.75 Proteome Sciences Plc Company Overview 170
5.75.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 170
5.76 Proteomics International Pty Ltd Company Overview 173
5.76.1 Proteomics International Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 173
5.77 Quanterix Corporation Company Overview 174
5.77.1 Quanterix Corporation Pipeline Products & Ongoing Clinical Trials Overview 174
5.78 Redox Diagnostics LLC Company Overview 175
5.78.1 Redox Diagnostics LLC Pipeline Products & Ongoing Clinical Trials Overview 175
5.79 Saladax Biomedical, Inc. Company Overview 176
5.79.1 Saladax Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 176
5.80 Satoris, Inc. Company Overview 177
5.80.1 Satoris, Inc. Pipeline Products & Ongoing Clinical Trials Overview 177
5.81 Scout Diagnostics, LLC Company Overview 178
5.81.1 Scout Diagnostics, LLC Pipeline Products & Ongoing Clinical Trials Overview 178
5.82 Singulex, Inc. Company Overview 179
5.82.1 Singulex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 179
5.83 SomaLogic, Inc. Company Overview 180
5.83.1 SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 180
5.84 Takeda Pharmaceuticals International AG Company Overview 181
5.84.1 Takeda Pharmaceuticals International AG Pipeline Products & Ongoing Clinical Trials Overview 181
5.85 The Johns Hopkins University Company Overview 183
5.85.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 183
5.86 The University of Melbourne Company Overview 184
5.86.1 The University of Melbourne Pipeline Products & Ongoing Clinical Trials Overview 184
5.87 Trinity College Dublin Company Overview 185
5.87.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 185
5.88 True Diagnostics, Inc. Company Overview 186
5.88.1 True Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 186
5.89 University of California, Irvine Company Overview 187
5.89.1 University of California, Irvine Pipeline Products & Ongoing Clinical Trials Overview 187
5.90 University of Chicago Company Overview 188
5.90.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 188
5.91 University of Georgia Company Overview 189
5.91.1 University of Georgia Pipeline Products & Ongoing Clinical Trials Overview 189
5.92 University of Luxembourg Company Overview 190
5.92.1 University of Luxembourg Pipeline Products & Ongoing Clinical Trials Overview 190
5.93 University of Nottingham Company Overview 191
5.93.1 University of Nottingham Pipeline Products & Ongoing Clinical Trials Overview 191
5.94 University of South Florida Company Overview 192
5.94.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 192
5.95 University of Texas Health Science Center at Houston Company Overview 193
5.95.1 University of Texas Health Science Center at Houston Pipeline Products & Ongoing Clinical Trials Overview 193
5.96 University of Texas Southwestern Medical Center at Dallas Company Overview 195
5.96.1 University of Texas Southwestern Medical Center at Dallas Pipeline Products & Ongoing Clinical Trials Overview 195
5.97 US Biomarkers, Inc. Company Overview 197
5.97.1 US Biomarkers, Inc. Pipeline Products & Ongoing Clinical Trials Overview 197
5.98 Vermillion, Inc. Company Overview 198
5.98.1 Vermillion, Inc. Pipeline Products & Ongoing Clinical Trials Overview 198
5.99 Vitruvian Biomedical, Inc. Company Overview 200
5.99.1 Vitruvian Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 200
5.100 Washington University in St. Louis Company Overview 201
5.100.1 Washington University in St. Louis Pipeline Products & Ongoing Clinical Trials Overview 201
5.101 XRGenomics LTD Company Overview 205
5.101.1 XRGenomics LTD Pipeline Products & Ongoing Clinical Trials Overview 205
5.102 Zoiray Technologies Inc. Company Overview 206
5.102.1 Zoiray Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 206
6 Alzheimer- Recent Developments 207
7 Appendix 213
7.1 Methodology 213
7.2 About GlobalData 215
7.3 Contact Us 216
7.4 Disclaimer 216
【レポート販売概要】
■ タイトル：世界のアルツハイマー検査機器開発動向：医療機器パイプライン分析2015■ 英文：Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2015
■ 発行日：2016年1月5日
■ 調査会社：GlobalData
■ 商品コード：GDME0143EPD
■ 調査対象地域：グローバル
- 世界の医療デバイスのコーティング市場動向（2012-2016）TechNavio's analysts forecast the Global Medical Device Coatings market to grow at a CAGR of 8.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased awareness of minimally invasive surgeries. The Global Medical Device Coatings Market has also been witnessing an increased use of super hydrophilic coating in medical devices. However, the reg …
- 世界の整形外科用生体材料市場Orthopaedic biomaterials market is expected to grow at a CAGR of 11% for the forecasted period of 2015-2021. Orthopedic materials are defined as materials used for internal fracture fixation; biomaterials are used for manufacturing bone implants. Biomaterials are composed of organic or synthetic materials. Biomaterials help in repairing the structural integrity of the damaged bones and joints. The …
- パルミチン酸ビタミンAの世界市場2015Vitamin A Palmitate (CAS 79-81-2) Market Research Report 2015 aims at providing comprehensive data on Vitamin A Palmitate market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Vitamin A Palmitate description, covers its application areas, manufacturing methods, patterns. It captures Vitamin A Palmitate market trends, pays close attention to Vitamin A …
- Tarceva (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）Tarceva (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment land …
- 低侵襲性手術機器の世界市場：手持ち器具、ガイド装置、拡張装置、切断装置The minimally invasive surgical instruments market is projected to reach USD 18.14 Billion by 2021 from USD 11.16 Billion in 2016, at a CAGR of 10.2%. Benefits of minimally invasive surgeries over traditional open surgeries; reduction in healthcare costs and time; increasing number of surgeries among the aging population; increasing prevalence of lifestyle disorders; and technological advancements …
- 世界のホット飲料市場のM&A動向（2014年6月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global hot drinks market during June 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global hot drinks market throughout the month. Additionally, the report provides an overview of all the partn …
- 米国の患者診察機器市場見通し（～2021）United States Patient Examination Devices Market Outlook to 2021 Summary GlobalData’s new report, "United States Patient Examination Devices Market Outlook to 2021", provides key market data on the United States Patient Examination Devices market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Stethoscopes an …
- 世界のメッセージングプラットフォーム市場動向：Global Messaging Platform Market 2014-2018TechNavio's analysts forecast the Global Messaging Platform market to grow at a CAGR of 8.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the high demand for internal collaboration. The Global Messaging Platform market has also been witnessing the increasing adoption of enterprise social tools. However, the lack of integration with legacy systems …
- テレマティクス：技術、事業機会、特許分析Coupled with the ever-evolving ICT and electronic control system technologies, telematics that enable the integration of computing, communications, control, and transport technologies has witnessed a bloom over the years. This report provides an overview of telematics development and its market outlook; examines strategic and patent deployment of established players in the industry such as Bosch, …
- Respiratory Diseases in the UK 2014: Market Outlook and Emerging OpportunitiesAbout This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the UK Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals, Commercial and Public Health Labs.In additio …
- フルオロケミカルの世界市場：インサイト、市場機会、市場シェア、市場予測The global fluorochemicals market has projected to produce 5,398.2 kilo tons by 2022, rising at a CAGR of 4.3% from 2016 to 2022. Increasing demand for automotive, refrigerants, and aluminum in the developing countries is anticipated to increase the demand of fluorochemicals. Refrigerants market had generated $14.80 billion in 2014 and is expected to generate up to $23.60 billion in 2022. The majo …
- IoT（モノのインターネット）の世界市場2015-2019About Internet of Things The Internet of Things (IoT) is a network of physical tangible objects interconnected through various network technologies. These objects can communicate among themselves and with the external environment when required. IoT facilitates an interconnection of end-user devices and the underlying communication devices. IoT combines hardware, embedded software, communication se …
- 世界の教育産業における電子ペーパーディスプレイ市場Electronic paper display or e-paper display is a portable, reusable electronic display medium, which has paper-like properties such as wide viewing angle, high flexibility, and no backlight. With new developments in e-paper displays such as increasing flexibility and ability to display all colours, the demand for e-paper displays is expected to surge in the future. Technologies that are being used …
- グローバルにおける高機能材料市場（2014-2018）About Advanced Functional Materials Advanced functional materials are a class of energy-efficient materials that contribute to sustainability. They are known to consume less energy during manufacture, use, and recycling, and therefore provide the benefit of a lower carbon footprint. There are five major types of advanced functional materials, which are used in low carbon applications: advanced fun …
- フレキシタンクの世界市場分析：製品別（シングルトリップ、マルチトリップ）、用途別（食品、ワイン･スピリッツ、化学薬品、オイル、工業製品、医薬品）、セグメント予測The global flexitanks market is expected to reach USD 1.49 billion by 2024, according to a new report by Grand View Research, Inc. Increasing commodity export, particularly in Asia Pacific, is expected to foster flexitanks demand over the forecast period. Cost-effective and efficient nature of flexitanks has increased product popularity among the end-users. Flexitanks can carry more amount of liqu …
